Gastrointestinal Very common (10% or more): Nausea (up to 18%), diarrhea (up to 17%) Common (1% to 10%): Vomiting, constipation, dyspepsia, abdominal pain, eructation, flatulence, gastroesophageal reflux disease, abdominal distension Uncommon (0.1% to 1%): Cholelithiasis, acute pancreatitis, increased serum pancreatic amylase levels, increased serum lipase levels, acute gallbladder disease (including cholelithiasis, biliary colic and cholecystectomy) Postmarketing reports : Ileus In pooled placebo-controlled trials, treatment with this drug resulted in mean increases from baseline in serum pancreatic amylase levels of up to 38% and serum lipase levels of up to 42%
& Niijima, A
GBM cells were exposed to the dendriplex for 72 h, and PURE G4 -LA 12 -anti- GLS1 -siRNA efficiently delivered the siRNA to the cell, leading to the knockdown of GLS1 in both cell lines (Fig
The State of Insurance Coverage in 2025 While the results of taking GLP-1 medications are clear, the insurance landscape looks different depending on where you stand
